Pablo Hernáiz Driever

Mar 11, 2024 | nature.com | Lindsay B. Kilburn |Dong-Anh Khuong-Quang |Jordan Hansford |Pablo Hernáiz Driever |Simon T. Bailey |David Ziegler | +10 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02668-y, published online 17 November 2023. In the version of the article initially published, in the third paragraph of the “RAPNO criteria (secondary endpoints)” section, the text now reading “Thirteen (17.1%) patients initially had a best overall response of PD…” originally read “Thirty-one patients initially had PD…”. This has been corrected in the HTML and PDF versions of the article.

Nov 17, 2023 | nature.com | Lindsay B. Kilburn |Dong-Anh Khuong-Quang |Jordan Hansford |Pablo Hernáiz Driever |Simon T. Bailey |David Ziegler | +10 more

AbstractBRAF genomic alterations are the most common oncogenic drivers in pediatric low-grade glioma (pLGG). Arm 1 (n = 77) of the ongoing phase 2 FIREFLY-1 (PNOC026) trial investigated the efficacy of the oral, selective, central nervous system–penetrant, type II RAF inhibitor tovorafenib (420 mg m−2 once weekly; 600 mg maximum) in patients with BRAF-altered, relapsed/refractory pLGG.

Oct 24, 2023 | nature.com | Dominik Sturm |David Capper |Felipe Andreiuolo |Christian Kölsche |Philipp Sievers |Annika K Wefers | +17 more

Correction to: Nature Medicine https://doi.org/10.1038/s41591-023-02255-1. Published online 16 March 2023. In the version of this article initially published, Arend Koch (Department of Neuropathology, Charité - Universitätsmedizin Berlin, Berlin, Germany), Martin U. Schuhmann (Department of Neurosurgery, University of Tuebingen, Tuebingen, Germany) and Ulrich W.

Mar 16, 2023 | nature.com | Dominik Sturm |David Capper |Felipe Andreiuolo |Philipp Sievers |Annika K Wefers |Ulrich Schüller | +17 more

AbstractThe large diversity of central nervous system (CNS) tumor types in children and adolescents results in disparate patient outcomes and renders accurate diagnosis challenging. In this study, we prospectively integrated DNA methylation profiling and targeted gene panel sequencing with blinded neuropathological reference diagnostics for a population-based cohort of more than 1,200 newly diagnosed pediatric patients with CNS tumors, to assess their utility in routine neuropathology.